Details checkedStatus confirmedHistorical/discontinuedCheckedcompany

FX-345 by Frequency Therapeutics

Also known as: FX-345, FX-345-101

Frequency Therapeutics

Primary source

Company

Frequency Therapeutics

Program Type

Therapeutic

Modality

Regenerative Medicine

Stage

Phase 1

Status

Discontinued

Target Gene

—

Route / Mode

Intratympanic injection

Confidence

95%

Status Confidence

Status confirmed

Evidence Strength

Needs more support

Last Reviewed

2026-05-31

Geography

United States

Population

adult

Trial IDs

Mechanism

Second-generation intratympanic small-molecule regenerative program designed for broader cochlear exposure than FX-322.

Indications

Hearing Loss Sensorineural Hearing Loss

Notes

Second-generation successor to FX-322; discontinued alongside FX-322 after Frequency exited hearing-loss R&D.

Evidence & Sources

2 structured sources

company

Supports: canonicalName, aliases, stage, route, company, allCompanies

IDs: FX-345, FX-345-101

Open

company

Supports: status, notes

IDs: FX-345

Open

Key Events

2022-12-15

Frequency dosed the first patient in the Phase 1b FX-345 study

2023-02-13

Frequency discontinued FX-345 with the hearing-loss franchise

Clinical Trials (1)

NCT05664100

Related Programs

Otarmeni by Regeneron

Company: Regeneron Pharmaceuticals · Gene Therapy · Approved

PEDMARK by Fennec Pharmaceuticals

Company: Fennec Pharmaceuticals · Small Molecule · Marketed

AK-OTOF by Eli Lilly and Akouos

Company: Eli Lilly and Company · Gene Therapy · Phase 2

SENS-401 (Arazasetron) by Sensorion

Company: Sensorion · Small Molecule · Phase 2

SENS-501 by Sensorion

Company: Sensorion · Gene Therapy · Phase 1/2

Rincell-1 by Rinri Therapeutics

Company: Rinri Therapeutics · Cell Therapy · Phase 1/2